Actual questions of increasing the availability of innovative therapy and the organization of medical care for patients with atherosclerotic cardiovascular diseases in the Russian Federation. Advisory Board

Authors

I. V. Sergienko "National Medical Research Center of Cardiology" of the Ministry of Health of the Russian Federation
S. V. Nedogoda Volgograd State Medical University, Ministry of Health of the Russian Federation, Volgograd
A. L. Vertkin State University of Medicine and Dentistry named after A.I. A.I. Evdokimov of the Ministry of Health of Russia, Moscow
M. G. Glezer First Moscow State Medical University named after A.I. I.M. Sechenov, Ministry of Health of Russia (Sechenov University), Moscow
V. S. Gurevich St. Petersburg State University, St. Petersburg
N. B. Gornyakova "National Medical Research Center of Cardiology" of the Ministry of Health of the Russian Federation
N. V. Babkova All-Russian Union of Public Associations of Patients
M. V. Zhuravleva Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation
S. K. Zyryanov Peoples' Friendship University of Russia, Moscow
E. D. Kosmacheva Kuban State Medical University, Krasnodar
V. V. Ryazhenov First Moscow State Medical University named after A.I. I.M. Sechenov, Ministry of Health of Russia (Sechenov University), Moscow
S. A. Shalnova "National Medical Research Center for Therapy and Preventive Medicine, Ministry of Health of Russia, Moscow
M. Yu. Frolov Volgograd State Medical University, Ministry of Health of the Russian Federation, Volgograd
M. V. Ezhov "National Medical Research Center of Cardiology" of the Ministry of Health of the Russian Federation

DOI:

https://doi.org/10.34687/2219-8202.JAD.2022.04.0006

Keywords:

Inclisiran, small interfering RNA, atherosclerosis, dyslipidemia, achievement of target levels of LDL-C

Abstract

In the conclusion of the Advisory Board, the possibility of a fundamentally new effect on the development and progression of atherosclerosis using a new lipid-lowering drug with small interfering RNA Inсlisiran is considered. The relevance of the problem of atherosclerosis, achieving the target level of LDL cholesterol, and the possibility of lipid-lowering therapy are considered. The mechanism of action of Inclisiran is described, the results of the main clinical studies with this drug (ORION program) are presented. Clinical guidelines that include Inclisiran are considered. The issue of a radically new possibility of influencing cardiovascular mortality in the Russian Federation is discussed.

Downloads

Download data is not yet available.

References

Проект Российских рекомендаций по нарушениям липидного обмена, год утверждения 2022, код по МКБ 10: E78.0/ E78.1/ E78.2/ E78.3/ E78.4 Возрастная группа: взрослые

Bandyopadhyay D., Qureshi A., Ghosh S., et al. Safety and Efficacy of Extremely Low LDL-Cholesterol Levels and Its Prospects in Hyperlipidemia Management J Lipids. 2018; 2018: 8598054

Ridker P.M., Everett B.M., Thuren T.M. et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease N Engl J Med 2017; 377:1119-1131

Hennessy Th., Soh L., Bowman M., Kurup R., Schultz C., Patel S., Hillis G.S. The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: A pilot randomized placebo controlled trial of colchicine following acute myocardial infarction Am Heart J 2019 Sep;215:62-69.

Baigent C, Keech A, Kearney PM, et. al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 Oct 8;366(9493):1267-78.

Sabatine M.S., et al. Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial Am Heart J. 2016;173:94-101.

Ray K.K. et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2019 Aug;7(8):618-628.

Ray KK, et. al. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. Eur J Prev Cardiol. 2021 Sep 20;28(11):1279-1289.

Mach F, Baigent C, Catapano AL, Koskinas KC, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-188.

Ray K.K. et al. Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe – Methodology and rationale for the multinational observational SANTORINI study. Atherosclerosis Plus Volume 43, September 2021, Pages 24-30

Raal FJ, et. al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020 Apr 16;382(16):1520-1530.Ray KK, et. al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020 Apr 16;382(16):1507-1519.

Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros M, Wijngaard PLJ, Kastelein JJP; ORION-10 and ORION-11 Investigators. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020 Apr 16;382(16):1507-1519.

Wright RS, et. al. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. J Am Coll Cardiol. 2021 Mar 9;77(9):1182-1193.

Merćep I, Friščić N, Strikić D, Reiner Ž. Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9-A Narrative Review. Cardiovasc Ther. 2022 Feb 10;2022:8129513.

Khan S.A, Naz A., Masoo M.Q., et al. Meta-analysis of inclisiran for the treatment of hypercholesterolemia. Am J Cardiol 2020; 134: 69-73

Cordero A., Santos-Gallego C.G., Facila L., et al. Estimation of the major cardiovascular events prevention with Inclisiran. Atherosclerosis 2020; 313: 76-80

Kallend D. et al. Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, inpatients with hepatic impairment. Journal of Clinical Lipidology 2022

Wright RS, Collins MG, et al. Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies. Mayo Clin Proc. 2020 Jan;95(1):77-89.

Lipid modification therapy for preventing cardiovascular disease. NICE 2022 http://pathways.nice.org.uk/pathways/cardiovascular-disease-prevention

PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021; Arch Med Sci 2021; 6:1148-1547

Brandts J, Ray KK. Low Density Lipoprotein Cholesterol-Lowering Strategies and Population Health: Time to Move to a Cumulative Exposure Model. Circulation. 2020 Mar 17;141(11):873-876.

Downloads

PDF (Русский)

Published

2022-11-28

How to Cite

Sergienko I. V., Nedogoda S. V., Vertkin A. L. ., Glezer M. G. ., Gurevich V. S. ., Gornyakova N. B., Babkova N. V. ., Zhuravleva M. V. ., Zyryanov S. K. ., Kosmacheva E. D. ., Ryazhenov V. V. ., Shalnova S. A. ., Frolov M. Y. ., Ezhov M. V. . Actual questions of increasing the availability of innovative therapy and the organization of medical care for patients with atherosclerotic cardiovascular diseases in the Russian Federation. Advisory Board // The Journal of Atherosclerosis and Dyslipidemias. 2022. VOL. № 4 (49). PP. 54–61.

MLA
GOST

Download Citation

Issue

No. 4 (49) (2022)

Section

Original research paper

License

Copyright (c) 2022 И. В. Сергиенко, C. В. Недогода, А. Л. Верткин, М. Г. Глезер, В. С. Гуревич, Н. Б. Горнякова, Н. В. Бабкова, М. В. Журавлёва, С. К. Зырянов, Е. Д. Космачева, В. В. Ряженов, С. А. Шальнова, М. Ю. Фролов, М. В. Ежов

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Crossref

Scopus

Google Scholar

Europe PMC

Most read articles by the same author(s)

M. V. Ezhov, I. V. Sergienko, V. V. Kukharchuk, Clinical guidelines for lipid disorders 2023. What's new? , The Journal of Atherosclerosis and Dyslipidemias: No. 3 (52) (2023)
M. V. Ezhov, I. V. Sergienko, N. M. Akhmedzhanov, V. S. Gurevich, A. G. Obrezan, Dyslipidemia 2022 – how to reduce the risk and achieve the goal? , The Journal of Atherosclerosis and Dyslipidemias: No. 3 (48) (2022)
P. S. Sadovnikov, A. Yu. Olkhovik, V. S. Gurevich, Calculation method for the low-density lipoprotein cholesterol levels on the basis of the lipid metabolism modern paradigm , The Journal of Atherosclerosis and Dyslipidemias: No. 3 (48) (2022)
V. V. Kukharchuk, M. V. Ezhov, I. V. Sergienko, G. G. Arabidze, M. G. Bubnova, T. V. Balakhonova, V. S. Gurevich, M. A. Kachkovsky, G. A. Konovalov, V. O. Konstantinov, P. P. Malyshev , S. D. Pokrovsky, A. A. Sokolov, A. B. Sumarokov, N. B. Gornyakova, A. G. Obrezan, I. I. Shaposhnik, M. B. Antsiferov, A. A. Ansheles, D. M. Aronov, N. M. Akhmedzhanov, O. L. Barbarash , S. A. Boitsov, M. I. Voivoda, G. R. Galstyan, A. S. Galyavich, O. M. Drapkina, D. V. Duplyakov, S. Ya. Eregin, R. S. Karpov, Yu. A. Karpov, N. A. Koziolova, E. D. Kosmachev, D. V. Nebieridze, S. V. Nedogoda, V. E. Oleynikov, Yu. I. Ragino, V. V. Skibitsky, O. G. Smolenskaya, A. E. Filippov, Yu. Sh. Halimov, I. E. Chazova, M. V. Shestakova, S. S. Yakushin, Diagnostics and correction of lipid metabolism disorders in order to prevent and treat of atherosclerosis Russian recommendations VII revision. Moscow, 2020 , The Journal of Atherosclerosis and Dyslipidemias: No. 1 (38) (2020)
I. V. Sergienko, M. V. Ezhov, V. S. Gurevich, V. K. Zafiraki, P. A. Barov, O. V. Tsygankova, E. A. Tsyplenkova, E. P. Prikhodko, N. G. Vinogradova, V. R. Idiyatullina, E. V. Vyrupaeva, M. V. Savchenko, Yu. E. Yukhina, A. A. Kalinovskaya, E. S. Timoshchenko, A. A. Nekrasov, O. G. Smolenskaya, K. S. Manko, E. V. Timoshina, Comparative efficacy and safety of statin monotherapy and their combination with ezetimibe (Results of the Russian retrospective observational study UNISON) , The Journal of Atherosclerosis and Dyslipidemias: No. 4 (49) (2022)
U. V. Chubykina, M. V. Ezhov, T. A. Rozhkova , B. M. Tamaeva, A. A. Sokolov, A. I. Ershova, A. N Meshkov, V. I. Mikhailina, A. V. Blokhina, A. S. Limonova, O. V. Kopylova, I. I. Shaposhnik, V. V. Genkel , V. S. Gurevich, S. A. Urazgildeeva, A. V. Tregubov, M. V. Muzalevskaya, M. I. Voevoda, O. V. Timoshchenko, E. V. Shakhtshneider, Yu. I. Ragino, I. V. Leontyeva, L. V. Egorov, I. N. Zakharova, I.I. Pshenichnikova, D. I. Sadykova, E. S. Slastnikova, L. F. Galimova, E. D. Kosmacheva, A. M. Namitokov, A. S. Alieva, A. S. Galyavich, Z. F. Kim, V. A. Korneva, T. Yu. Kuznetsova, A. E. Filippov, A. M. Tuktarov, A. S. Vorobyov, I. D. Astrakhantseva, D. Yu. Bogdanov, M. A. Kachkovsky, A. V. Egorova, V. O. Konstantinov, M. P. Serebrenitskaya, V. K. Zafiraki, N. N. Bizyaeva, N. G. Androsyuk, M. A. Kiseleva, Yu. G. Grigorieva, O.Yu. Korennova, Yu. E. Yukhina, M. D. Devyatova, O. N. Ivanova, P. A. Vasiliev, I. V. Avdeeva, V. E. Oleinikov, Yu. A. Vorobieva, Yu. A. Ermakova, N. V. Mukha, D. N. Zaitsev, M. V. Zykov, A.V. Isaeva, T. I. Petelina, E. V. Mikova, A five-year follow-up period in homo- and heterozygous familial hypercholesterolemia patients of the RENAISSANCE registry , The Journal of Atherosclerosis and Dyslipidemias: No. 1(50) (2023)
M. V. Ezhov, S. S. Bazhan, A. I. Ershova, A. N. Meshkov, A. A. Sokolov, V. V. Kukharchuk, V. S. Gurevich, M. I. Voevoda, I. V. Sergienko, E. V. Shakhtshneider, S. N. Pokrovsky, G. A. Konovalov, I. V. Leontyeva, V. O. Konstantinov, M. Yu. Shcherbakova, I. N. Zakharova, T. V. Balakhonova, A. E. Filippov, N. M. Akhmedzhanov, O. Yu. Aleksandrova, B. M. Lipovetsky, Clinical guidelines for familial hypercholesterolemia , The Journal of Atherosclerosis and Dyslipidemias: No. 1 (34) (2019)
I. V. Sergienko, M. V. Shestakova, S. A. Boystov, A. S. Ametov, M. B. Antsiferov, V. V. Kukharchuk, D. A. Zateishchikov, M. V. Ezhov, V. S. Gurevich, A. S. Galyavich, M. I. Voevoda, D. V. Duplyakov, O. L. Barbarash, Yu. Sh. Khalimov, G. P. Arutyunov, Yu. A. Karpov, M. G. Bubnova, L. Yu. Drozdova, A. A. Ansheles, I. V. Samorodskaya, N. A. Koziolova, O. M. Drapkina, Extreme risk category in the stratification system cardiovascular complications , The Journal of Atherosclerosis and Dyslipidemias: No. 4 (33) (2018)
M. V. Ezhov, I. V. Sergienko, D. M. Aronov, G. G. Arabidze, N. M. Akhmedzhanov, S. S. Bazhan, T. V. Balakhonova, O. L. Barbarash, S. A. Boytsov, M. G. Бубнова Bubnova, M. I. Voevoda, A. S. Galyavich, N. B. Gornyakova, V. S. Gurevich, O. M. Drapkina, D. V. Duplyakov, S. Ya. Yeregin, M. Yu. Zubareva, R.S. Karpov, Yu. A. Karpov, N. A. Koziolova, G. A. Konovalov, V. O. Konstantinov, E. D. Kosmacheva, A. I. Martynov, D. V. Nebieridze, S. N. Pokrovsky, Yu. I. Ragino, V. V. Skibitsky, O. G. Smolenskaya, I. E. Chazova, S. A. Shalnova, I. I. Shaposhnik, V. V. Kukharchuk , Diagnostics and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian recommendations VI revision , The Journal of Atherosclerosis and Dyslipidemias: No. 3 (28) (2017)
A. M. Schinova, A. V. Potekhina, Yu. A. Dolgusheva, Yu. E. Efremova, A. Yu. Filatova, A. K. Osokina, N. B. Gornyakova, E. A. Barabanova, I. I. Shestova, S. I. Provatorov, Medication adherence after myocardial infarction and methods for its improvement. , The Journal of Atherosclerosis and Dyslipidemias: No. 3 (48) (2022)

1 2 3 4 5 6 7 8 9 > >>